{"name":"Idience Co., Ltd.","slug":"idience-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQUVM4NElXTlNDa2pEOHhpOV9fXzBVMDRVVVpFUFlsSWoyV3JxWXNqNlZvMlpfM01EVWFzUzQ2aEw3Q3dPbWNUTkVweDhFRnc0bk9CV3JBZTRnR0JtQVY4ZGZWMHAtdGJfbkwtZWZTSUYzVzYwSUY1Y0hCaXNRaWFiONIBlAFBVV95cUxNbnJ3aU12Ym1fMUktNjR2OEdMd2RZR2hEYlRha0lvemJzUzFWSWsyRnJMaE8xOEYxc0lCWnhsTXJiUXdOdEpaenQtUENvU0U5N1BUVG9mS1BDdWw5eldadmgzLXNxZ0liTG9tQzRHQV9mTFJJd2JQOGZjUFdQWlYyY1RTeXk0Wi1zdk0zUG1ZM2NFVkcz?oc=5","date":"2025-10-23","type":"pipeline","source":"Chosunbiz","summary":"Korean pharma firms spin off R&D units to spread risk and speed drug development - CHOSUNBIZ - Chosunbiz","headline":"Korean pharma firms spin off R&D units to spread risk and speed drug development - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxOZTNhbUhNTmNqOFBXanlOa1pBN1RRMlNTZEtoVW9yYkJGSVBUVy1jM1pMUmlDZnJlNUtWVFFscXJjODdMUWM5QjJJY1dCeVZwQ3hSdXV1VTVBV3NQUHVtOGdSSU5wc2dJQXNxbmVZX2xITGVLUk92TU5EaldGSi1jNmVBQVhiZEF6MGlldkFhUEEtQzU2ZzJpM3NZTmtQMEZPVGw1M1l4Y2o3S2tNWGhvUTFDNWh1dkhwQURHQW4xc191MFpKWmF2UGlyVlRpWHVidkJYbmkwLWE4OEpXMmRIeTA1OERHdENqaERCYkwxSThJUm8?oc=5","date":"2025-07-23","type":"pipeline","source":"PR Newswire","summary":"Claudin 18.2-Directed Oncology Therapeutics--A Fast-Growing Market with Blockbuster Potential | DelveInsight - PR Newswire","headline":"Claudin 18.2-Directed Oncology Therapeutics--A Fast-Growing Market with Blockbuster Potential | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQcTF2VnliUm5rU0dxZ2tMUEZxTTJTaGVpaGw3SDEySF92TWlHZktUVkVjNWhlS1FuX1BqVUtXTWpISXhiNEE5ckN6RkwzZnpuV2dyYWtiYkdfeEZuUWlCMXNsZjhkcTFmQzU2TWsxZTlZaUpjdWNjUVJGVjk3XzhDZy0ySGVuQ2k5ODgwU0xIbkxLcVVWT2NLdVdvcFM5ZVU?oc=5","date":"2024-06-10","type":"pipeline","source":"BioWorld News","summary":"Abtis tapping ADC market with Claudin18.2-targeting AT-211 - BioWorld News","headline":"Abtis tapping ADC market with Claudin18.2-targeting AT-211","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9nNVN3WHpWQ2puMERvV2lfTHV4TXR1RVpxZ29Cc2tnVUtZNEhsYktMdlpxZHUxbmIxX3RiVG5JX2E2WWdjcWV6bUl0Q2JqZ0RhRndfYzk1V1YxTGxT?oc=5","date":"2024-03-19","type":"trial","source":"EurekAlert!","summary":"New data show pembrolizumab improves breast cancer outcomes regardless of age or menopausal status - EurekAlert!","headline":"New data show pembrolizumab improves breast cancer outcomes regardless of age or menopausal status - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxORC1lWmJibWVrTHZfM1diTzJqaTFuM1ZNaUZCaVZLZlphQmZNbFNTR0NPcXo2ZVk3TDRuekJEUXgzUGRiazJkUFN5X0xLODFRWmd2bUZuWlFwSl9tcFJreGhzODFLdUVtS0szZXM1Qk1UZHkteHdXM3p2c3JISnpBMjNoWTNrRUZXZzhRdFFR?oc=5","date":"2023-08-01","type":"trial","source":"Yahoo Finance","summary":"PARP Inhibitors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 20+ Leading Players Wheeling the Therapeutics Landscape - Yahoo Finance","headline":"PARP Inhibitors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 20+ Leadi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBfb3JTTm1CWC1fMjJvRGVNeHRVVmlQdUlTa1hrS0hUZWV1WU8tMnpaNkxiZHJybDdEcGNzNmE1V1phbnhtZjZOSUFRQXlPRl9FR2t5djhpeFBUUXZlZVVj?oc=5","date":"2020-09-01","type":"pipeline","source":"Nature","summary":"Idience: developing selective and potent PARP inhibitor IDX-1197 for solid tumors - Nature","headline":"Idience: developing selective and potent PARP inhibitor IDX-1197 for solid tumors","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}